SCHEMBL4766100

SCHEMBL4766100

N#CC(C(N)=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.49
ALDH1A1 P00352 6/20 0.48
TSHR P16473 1/20 0.47
PLAU P00749 1/20 0.45
MAPT P10636 3/20 0.43
CDK5 Q00535 1/20 0.43
CDK5R1 Q15078 1/20 0.43
HPGD P15428 1/20 0.41
CTSD P07339 1/20 0.41
POLB P06746 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
GPR35 Q9HC97 1/20 0.38
F2 P00734 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
SGMS2 Q8NHU3 1/20 0.38
CUL4A Q13619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6215287 0.86 CYP1A2 (0.58) CYP1A2ALDH1A1TSHRPLAUMAPT
SCHEMBL6215281 0.86 CYP1A2 (0.58) CYP1A2ALDH1A1TSHRPLAUMAPT
SCHEMBL1803059 0.81 ALDH1A1 (0.67) CYP1A2ALDH1A1TSHRMAPTCDK5
SCHEMBL3830559 0.80 VCAM1 (0.50) CYP1A2ALDH1A1TSHRMAPTHPGD
SCHEMBL3207172 0.80 S100A4 (0.37) CYP1A2ALDH1A1PLAUMAPTMEN1
SCHEMBL3831033 0.80 TDP1 (0.41) MAPT
SCHEMBL3836060 0.80 TSHR (0.46) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL3829455 0.80 TSHR (0.46) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL7677183 0.79 ALDH1A1 (0.56) CYP1A2ALDH1A1TSHRMAPTCDK5
SCHEMBL11341485 0.77 CYP1A2 (0.54) CYP1A2ALDH1A1TSHRPLAUMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124668-A1 NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-05-26 US disclosed
EP-1432715-B1 PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2008-03-19 EP disclosed
US-7312224-B2 Pyrimidine derivatives MERCK PATENT GMBH (DE) 2007-12-25 US disclosed
US-20040242595-A1 Pyrimidine derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-12-02 US disclosed
EP-1432715-A2 PYRIMIDINE DERIVATIVES MERCK PATENT GmbH (DE) 2004-06-30 EP disclosed
WO-2003031447-A2 PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124668-A1 NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP IKBKB, CHUK, RELA CYP1A2 3047/4885ALDH1A1 2063/4885TSHR 2214/4885
US-20040242595-A1 Pyrimidine derivatives TYMP, DPYD, TYMS CYP1A2 361/4885ALDH1A1 671/4885TSHR 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.